Drug developers were challenged to strive for new heights with novel antibody-drug conjugates in solid cancers during a discussion session at the 2017 American Society of Clinical Oncology (ASCO) annual meeting, held June 2-6 in Chicago.
The session focused on three early-stage clinical data presentations for novel antibody-drug conjugates (ADCs) from Seattle Genetics Inc.,







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)